- Visibility 53 Views
- Downloads 6 Downloads
- DOI 10.18231/j.ijcaap.2023.019
-
CrossMark
- Citation
Role of nanoparticles in pancreatic drug delivery: Including a bibliography on Targeted drug delivery
- Author Details:
-
Navni Sharma *
-
Vimal Arora
-
Gaurav Joshi
-
Bhupendra Gopalbhai Prajapati
-
Akshay Parihar
Background
Pancreatic cancer is a deadly disease because of its poor prognosis. The chances of the development of this cancer are increasing day by day. Through the physician, scientists got knowledge of advancements through the papers. As the growth of the disease increased, the publication rate also increased. In recent years, there is a huge difference inthe article published count than the previous ones. We received 298 articles by which 15 articles are cited more than 100 times. The main purpose of our analysis is to identify the top citations in the area of pancreatic cancer nanoparticle targeted drug delivery research.[1]
Materials and Methods
The information was collected using the SCOPUS database, which was launched by Elsevier and generated 298 results. [Table 3] lists the top 100 most cited papers in order of citation count. The article with the most citations received 298 while the item with the fewest received only 80. Over 100 citations were found in fourteen papers. The citations of a work from before 2006 that had been cited for 10 years with an average count for each paper was 62. [2]
|
Year |
Citations of 298 Documents |
Number of Papers |
|
<2006 |
0 |
0 |
|
2006 |
1 |
1 |
|
2007 |
8 |
0 |
|
2008 |
12 |
4 |
|
2009 |
38 |
3 |
|
2010 |
76 |
2 |
|
2011 |
113 |
7 |
|
2012 |
174 |
12 |
|
2013 |
249 |
10 |
|
2014 |
303 |
19 |
|
2015 |
404 |
27 |
|
2016 |
560 |
26 |
|
2017 |
761 |
36 |
|
2018 |
922 |
31 |
|
2019 |
1250 |
39 |
|
2020 |
1736 |
39 |
|
2021 |
1947 |
42 |
|
Total |
8554 |
298 |
|
Rank |
Reference Number |
Number of Citations |
Rank |
Reference Number |
Number of Citations |
|
1 |
280 |
35 |
70 |
||
|
2 |
230 |
36 |
68 |
||
|
3 |
209 |
37 |
68 |
||
|
4 |
157 |
38 |
66 |
||
|
5 |
151 |
39 |
64 |
||
|
6 |
148 |
40 |
64 |
||
|
7 |
145 |
41 |
64 |
||
|
8 |
142 |
42 |
63 |
||
|
9 |
140 |
43 |
63 |
||
|
10 |
125 |
44 |
62 |
||
|
11 |
124 |
45 |
61 |
||
|
12 |
112 |
46 |
60 |
||
|
13 |
111 |
47 |
58 |
||
|
14 |
109 |
48 |
57 |
||
|
15 |
100 |
49 |
57 |
||
|
16 |
97 |
50 |
54 |
||
|
17 |
96 |
51 |
54 |
||
|
18 |
95 |
52 |
54 |
||
|
19 |
94 |
53 |
54 |
||
|
20 |
93 |
54 |
53 |
||
|
21 |
88 |
55 |
52 |
||
|
22 |
86 |
56 |
52 |
||
|
23 |
86 |
57 |
51 |
||
|
24 |
84 |
58 |
50 |
||
|
25 |
80 |
59 |
49 |
||
|
26 |
80 |
60 |
49 |
||
|
27 |
76 |
61 |
48 |
||
|
28 |
75 |
62 |
48 |
||
|
29 |
74 |
63 |
48 |
||
|
30 |
73 |
64 |
48 |
||
|
31 |
72 |
65 |
47 |
||
|
32 |
71 |
66 |
47 |
||
|
33 |
71 |
67 |
47 |
||
|
34 |
70 |
68 |
47 |
|
Rank |
Journals |
Number of Article |
|
1 |
Journal of Controlled Release |
27 |
|
2 |
Theranostics |
12 |
|
3 |
International Journal of Nanomedicine |
10 |
|
4 |
Molecular Pharmaceutics |
7 |
|
5 |
Pharmacological Reviews |
6 |
|
6 |
Bioconjugate Chemistry |
5 |
|
7 |
Advanced Healthcare Materials |
3 |
|
7 |
Journal of Nanobiotechnology |
3 |
|
8 |
Frontiers in Pharmacology |
2 |
|
8 |
Molecular Therapy |
2 |
|
9 |
ActaPharmaceuticaSinica B |
1 |
|
10 |
Bioconjugate Chemistry |
1 |
|
11 |
BioImpacts |
1 |
|
12 |
Brazilian Journal of Pharmaceutical Sciences |
1 |
|
13 |
ChemMedChem |
1 |
|
14 |
Current Cancer Drug Targets |
1 |
|
15 |
Current Drug Delivery |
1 |
|
16 |
Current Drug Metabolism |
1 |
|
17 |
Current Drug Targets |
1 |
|
18 |
Current Medicinal Chemistry |
1 |
|
19 |
Current Pharmaceutical Design |
1 |
|
20 |
Drug Delivery |
1 |
|
21 |
Drug Resistance updates |
1 |
|
22 |
European Journal of Pharmaceutical Sciences |
1 |
|
23 |
European Journal of Pharmaceutics and Biopharmaceutics |
1 |
|
24 |
Journal of Clinical Pharmacology |
1 |
|
25 |
Journal of Pharmaceutical Analysis |
1 |
|
26 |
Journal of Pharmaceutical Sciences |
1 |
|
27 |
Molecular Therapy - Nucleic Acids |
1 |
|
28 |
Nanomedicine: Nanotechnology, Biology, and Medicine |
1 |
|
29 |
Nucleic Acid Therapeutics |
1 |
|
30 |
Pharmaceuticals |
1 |
|
31 |
Pharmaceutics |
1 |
|
Rank |
Country |
No. of Articles |
|
1 |
United States |
53 |
|
2 |
China |
16 |
|
3 |
Germany |
5 |
|
4 |
Iran |
3 |
|
4 |
Japan |
3 |
|
4 |
Poland |
3 |
|
4 |
South Korea |
3 |
|
5 |
India |
2 |
|
5 |
Italy |
2 |
|
6 |
Australia |
1 |
|
6 |
South Korea |
1 |
|
6 |
Estonia |
1 |
|
6 |
France |
1 |
|
6 |
Mexico |
1 |
|
6 |
Netherlands |
1 |
|
6 |
Portugal |
1 |
|
6 |
Switzerland |
1 |
|
6 |
Taiwan |
1 |
|
6 |
United Kingdom |
1 |
|
Rank |
Institution |
Number of Articles |
|
1 |
Yonsei University |
4 |
|
2 |
Department of Biomedical Engineering |
3 |
|
2 |
Department of Pharmaceutics |
3 |
|
3 |
Cancer Biology Research Centre |
2 |
|
3 |
Hampton University |
2 |
|
3 |
University of Colorado School of Pharmacy |
2 |
|
3 |
Department of Pharmacy |
2 |
|
3 |
Department of Surgery |
2 |
|
3 |
Department of Technology and Biotechnology of Drugs |
2 |
|
3 |
Experimental Pathology and Therapeutics Group |
2 |
|
3 |
Laboratory of Cytobiochemistry |
2 |
Results
The SCOPUS database, which was launched by Elsevier, was used to conduct the literature search, which yielded 298 results. [Table 3] shows the top 100 most referenced papers ranked by the number of citations. The article with the most citations earned 298 citations, while the article with the least citations saved 80. A total of fourteen articles saved over 100 citations. Each paper received an average of 62 citations. We also looked at the citations of a publication published before 2006 that had been cited for the previous ten years. The results indicate there was no document published and cited before 2006. In the year 2006 number of papers cited: and number of Paper published was 1:1, 2007 (8:0),2008 (12:4),2009 (38:3),2010 (76:2), 2011 (113:7), 2012 (174:12), 2013 (249:10), 2014 (303:19), 2015 (404:27), 2016 (560:26), 2017 (761:36), 2018 (922:31), 2019 (1250:39), 2020 (1736:39), and 2021(1947:42) respectively ([Table 2]).
The top-cited papers were published in 33 high-impact journals ([Table 4]), led by the Journal of Controlled Release (27 articles), Theranostics (12 articles), International Journal of Nanomedicine (10 articles), and Molecular Pharmaceutics (7 articles). The top 100 referenced papers came from 19 different nations, with the United States generating 53, China 16 and Germany 5 each ([Table 5]). These top 100 referenced publications were generated by 85 different universities. Eleven universities generated two or more of the top-cited publications ([Table 5]), with the Department of Chemical and Biomolecular Engineering leading the way with four articles, followed by the University of Texas with seven, and Harvard University with six (7 articles).
Discussion
A number of aims are served by bibliometric examination of the most frequently cited publications and the journals in which they appear. It acknowledges and emphasises the value of our predecessors' and colleagues' work, highlights major milestones in pancreatic cancer research, and provides helpful historical data. Citation analysis of published research on pancreatic cancer targeted drug delivery gives quantifiable information on authors, nations, and publications, aiding in the finding of high-impact works and journals. This is the first time, as far as we know, that a citation-based analysis of the top citations in pancreatic cancer research has been conducted. Although examining all 100 top citations in detail would be difficult, the top ten may reveal some interesting data.
These 10 notable citations have highlighted significant accomplishments in pancreatic cancer nanoparticle targeted drug delivery research and a variety of related fields throughout the preceding 50 years. The primary paper, written by P. Yingchoncharoen, detailed a lipid medicine delivery system for cancer therapy that might be the most important advancement in medical treatment research in decades. Many articles are still mentioned on a daily basis, and their citation is fully reliable on the passage of time, since the date of publication is a significant determinant in citation. As a consequence, modern works get less citations than older ones. However, no document was cited before 2006, and the years 2015-2021 had the most citations, with 27 and 42, respectively. It illustrates that changes in the previous six years have been more significant. In addition, each year, a huge number of new journals are founded, the number of published papers rises dramatically, and more references are referenced. Three journals namely Theranostics, Journal of Controlled Release, and International Journal of Nanomedicine published 27,12, and 10 papers respectively. This data suggests that these three journals were the most influential in the field of pancreatic cancer nanoparticles targeted drug delivery research. Molecular Pharmaceutics, Pharmacological Reviews, and Bioconjugate Chemistry were also excellent medical journals, with 18 papers published each.
Because this is an important issue and a major concern on a worldwide scale, the publication rate on this topic is consistently increasing in these journals. Another conclusion is that the majority of the most highly reference papers come from the United States. The United States is home to the majority of productive institutions. Because of its big population and funding agencies, the United States has a significant effect on targeted medication delivery for the treatment of pancreatic cancer. The United States government assists and supports the scientific community in their research. There were at least 100 top-cited publications in this review, however, the majority of them were document-type articles. A few of them are not original study papers, but they are classified as opinion pieces for future cancer research, which is why they are often mentioned. The top articles found while searching for "pancreatic cancer nanoparticles tailored ligand binding medication delivery" were mostly about cancer. This article may open up new avenues for medical study and aid in the identification of gaps in pancreatic cancer therapy.
Conclusion
The articles that received the most citations contributed to advancements in the field of pancreatic cancer research. This analysis identifies important advancements in pancreatic cancer and targeted drug delivery research, as well as providing a historical perspective on the history of pancreatic cancer research.
Source of Funding
None.
Conflict of Interest
None.
References
- Y Zhang, L Quan, L Du. The 100 top-cited studies in cancer immunotherapy. Artificial Cells, Nanomedicine, Biotechnol 2019. [Google Scholar] [Crossref]
- Q Li, Y Jiang. Top Classic Citations in Pancreatic Cancer Research. World J Surg Oncol 2016. [Google Scholar] [Crossref]
- P Cui, S Wang. Application of Microfluidic Chip Technology in Pharmaceutical Analysis: A Review. J Pharm Anal 2019. [Google Scholar]
- A Lowery, H Onishko, D E Hallahan, Z Han. Tumor-Targeted Delivery of Liposome-Encapsulated Doxorubicin by Use of a Peptide That Selectively Binds to Irradiated Tumors. J Controlled Release 2011. [Google Scholar] [Crossref]
- N Zhang, C Chittasupho, C Duangrat, TJ Siahaan, C Berkland. PLGA Nanoparticle-Peptide Conjugate Effectively Targets Intercellular Cell-Adhesion Molecule-1. Bioconjug Chem 2008. [Google Scholar] [Crossref]
- JL Santiago-Ortiz, DV Schaffer. Adeno-Associated Virus (AAV) Vectors in Cancer Gene Therapy. J Control Release 2016. [Google Scholar] [Crossref]
- C Szabo, A Papapetropoulos. International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. Pharmacol Rev 2017. [Google Scholar] [Crossref]
- MA Rahman, ARMR Amin, X Wang, JE Zuckerman, CHJ Choi, B Zhou. Systemic Delivery of SiRNA Nanoparticles Targeting RRM2 Suppresses Head and Neck Tumor Growth. J Control Release 2012. [Google Scholar] [Crossref]
- MM Yallapu, SF Othman, ET Curtis, NA Bauer, N Chauhan, D Kumar. Curcumin-Loaded Magnetic Nanoparticles for Breast Cancer Therapeutics and Imaging Applications. Int J Nanomedicine 2012. [Google Scholar] [Crossref]
- MW Ndinguri, R Solipuram, R P Gambrell, S Aggarwal, RP Hammer. Peptide Targeting of Platinum Anti-Cancer Drugs. Bioconjug Chem 2009. [Google Scholar] [Crossref]
- S Zhu, M Niu, H O’mary, Z Cui. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm 2013. [Google Scholar] [Crossref]
- S Gao, D Yang, Y Fang, X Lin, X Jin, Q Wang. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy. Theranostics 2019. [Google Scholar] [Crossref]
- B Mulloy, J Hogwood, E Gray, R Lever, CP Page. Pharmacology of Heparin and Related Drugs. Pharmacol Rev 2015. [Google Scholar] [Crossref]
- K Knoop, M Kolokythas, K Klutz, MJ Willhauck, N Wunderlich, D Draganovici. Image-Guided, Tumor Stroma-Targeted 131 i Therapy of Hepatocellular Cancer after Systemic Mesenchymal Stem Cell-Mediated Nis Gene Delivery. Mol Ther 2011. [Google Scholar] [Crossref]
- C Chittasupho, SX Xie, A Baoum, T Yakovleva, TJ Siahaan, CJ Berkland. ICAM-1 Targeting of Doxorubicin-Loaded PLGA Nanoparticles to Lung Epithelial Cells. Eur J Pharm Sci 2009. [Google Scholar]
- F Wang, M Porter, A Konstantopoulos, P Zhang, H Cui. Preclinical Development of Drug Delivery Systems for Paclitaxel-Based Cancer Chemotherapy. J Controlled Release 2017. [Google Scholar] [Crossref]
- D Irby, C Du, F Li. Lipid-Drug Conjugate for Enhancing Drug Delivery. Mol Pharm 2017. [Google Scholar] [Crossref]
- J Xu, F Gattacceca, M Amiji. Biodistribution and Pharmacokinetics of EGFR-Targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-Bearing Mice. Mol Pharm 2013. [Google Scholar] [Crossref]
- F Alexis, P Basto, E Levy-Nissenbaum, AF Radovic-Moreno, L Zhang, E Pridgen. HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem 2008. [Google Scholar] [Crossref]
- MP Melancon, RJ Stafford, C Li. Challenges to Effective Cancer Nanotheranostics. J Controlled Release 2012. [Google Scholar] [Crossref]
- V Sancho, A Di Florio, TW Moody, RT Jensen. Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status. Curr Drug Deliv 2011. [Google Scholar] [Crossref]
- W Wang, M Xi, X Duan, Y Wang, FE Kong. Delivery of Baicalein and Paclitaxel Using Self-Assembled Nanoparticles: Synergistic Antitumor Effect in Vitro and in Vivo. Int J Nanomedicine 2015. [Google Scholar] [Crossref]
- J Intra, AK Salem. Characterization of the Transgene Expression Generated by Branched and Linear Polyethylenimine-Plasmid DNA Nanoparticles in Vitro and after Intraperitoneal Injection in Vivo. J Controlled Release 2008. [Google Scholar] [Crossref]
- SKS Kushwaha, S Ghoshal, AK Rai, S Singh. Carbon Nanotubes as a Novel Drug Delivery System for Anticancer Therapy: A review. Braz J Pharm Sci 2013. [Google Scholar] [Crossref]
- JC Sunshine, DY Peng, JJ Green. Uptake and Transfection with Polymeric Nanoparticles Are Dependent on Polymer End-Group Structure, but Largely Independent of Nanoparticle Physical and Chemical Properties. Mol Pharm 2012. [Google Scholar]
- H Shi, X Gao, D Li, Q Zhang, Y Wang, Y Zheng. A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiation. Int J Nanomedicine 2012. [Google Scholar] [Crossref]
- VJ Yao, S Angelo, KS Butler, C Theron, TL Smith, S Marchiò. Ligand-Targeted Theranostic Nanomedicines against Cancer. J Control Release 2016. [Google Scholar] [Crossref]
- O Mashinchian, M Johari-Ahar, B Ghaemi, M Rashidi, J Barar, Y Omidi. Impacts of Quantum Dots in Molecular Detection and Bioimaging of Cancer. Bioimpacts 2014. [Google Scholar] [Crossref]
- JA Ferreira, A Peixoto, M Neves, C Gaiteiro, CA Reis, YG Assaraf. Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resist Updat 2016. [Google Scholar] [Crossref]
- T Sun, Y Wang, Y Wang, J Xu, X Zhao, S Vangveravong. Using Sv119-Gold Nanocage Conjugates to Eradicate Cancer Stem Cells through a Combination of Photothermal and Chemo Therapies. Adv Healthc Mater 2014. [Google Scholar] [Crossref]
- J Park, J Park, Y Pei, J Xu, Y Yeo. Pharmacokinetics and Biodistribution of Recently-Developed SiRNA Nanomedicines. Adv Drug Deliv Rev 2016. [Google Scholar] [Crossref]
- S Sun, E Shang, A Ju, Y Li, Q Wu, Q Li. Tumor-Targeted Hyaluronic Acid-MPEG Modified Nanostructured Lipid Carriers for Cantharidin Delivery: An in Vivo and in Vitro Study. Fitoterapia 2021. [Google Scholar] [Crossref]
- MS Bhojani, M Van Dort, A Rehemtulla, BD Ross. Targeted Imaging and Therapy of Brain Cancer Using Theranostic Nanoparticles. Mol Pharm 2010. [Google Scholar] [Crossref]
- S Nordmeier, W Ke, K A Afonin, V Portnoy. Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs). Nanomedicine 2020. [Google Scholar] [Crossref]
- A Wei, JG Mehtala, AK Patri. Challenges and Opportunities in the Advancement of Nanomedicines. J Controlled Release 2012. [Google Scholar] [Crossref]
- MA Sandoval, BR Sloat, P Lansakara, DSP Kumar, A Rodriguez, B L Kiguchi. EGFR-Targeted Stearoyl Gemcitabine Nanoparticles Show Enhanced Anti-Tumor Activity. J Controlled Release 2012. [Google Scholar] [Crossref]
- P Singh, G Destito, A Schneemann, M Manchester. Canine Parvovirus-like Particles, a Novel Nanomaterial for Tumor Targeting. J Nanobiotechnol 2006. [Google Scholar] [Crossref]
- KJ Isaacson, M Martin Jensen, NB Subrahmanyam, H Ghandehari. Matrix-Metalloproteinases as Targets for Controlled Delivery in Cancer: An Analysis of Upregulation and Expression. J Controlled Release 2017. [Google Scholar] [Crossref]
- L Xu, T Anchordoquy. Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based Therapeutics. J Pharm Sci 2011. [Google Scholar] [Crossref]
- PH Wu, Y Onodera, Y Ichikawa, E B Rankin, AJ Giaccia, Y Watanabe. Targeting Integrins with RGD-Conjugated Gold Nanoparticles in Radiotherapy Decreases the Invasive Activity of Breast Cancer Cells. Int J Nanomedicine 2017. [Google Scholar] [Crossref]
- J Park, Y Choi, H Chang, W Um, JH Ryu, IC Kwon. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment. Theranostics 2019. [Google Scholar] [Crossref]
- S Chen, SK Boda, SK Batra, X Li, J Xie. Emerging Roles of Electrospun Nanofibers in Cancer Research. Adv Healthc Mater 2018. [Google Scholar] [Crossref]
- G Lin, H Zhang, L Huang. Smart Polymeric Nanoparticles for Cancer Gene Delivery. Mol Pharm 2015. [Google Scholar] [Crossref]
- M Khoshnejad, H Parhiz, VV Shuvaev, IJ Dmochowski, VR Muzykantov. Ferritin-Based Drug Delivery Systems: Hybrid Nanocarriers for Vascular Immunotargeting. J Controlled Release 2018. [Google Scholar] [Crossref]
- J Barar, M A Rafi, M M Pourseif, Y Omidi. Blood-Brain Barrier Transport Machineries and Targeted Therapy of Brain Diseases. BioImpacts 2016. [Google Scholar] [Crossref]
- J Huang, F Liu, X Han, L Zhang, Z Hu, Q Jiang. Nanosonosensitizers for Highly Efficient Sonodynamic Cancer Theranostics. Theranostics 2018. [Google Scholar] [Crossref]
- V Sanna, N Pala, G Dessì, P Manconi, A Mariani, S Dedola, C Crosio, C Iaccarino. Single-Step Green Synthesis and Characterization of Gold-Conjugated Polyphenol Nanoparticles with Antioxidant and Biological Activities. Int J Nanomedicine 2014. [Google Scholar] [Crossref]
- R Gilabert-Oriol, A Weng, B Von Mallinckrodt, MF Melzig, H Fuchs, M Thakur. Immunotoxins Constructed with Ribosome-Inactivating Proteins and Their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy. Curr Pharm Design 2014. [Google Scholar] [Crossref]
- D Liu, D T Auguste. Cancer Targeted Therapeutics: From Molecules to Drug Delivery Vehicles. Journal of Controlled Release2015 . [Google Scholar]
- G Battogtokh, YY Cho, JY Lee, HS Lee, HC Kang. Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment. Front Pharmacol 2018. [Google Scholar] [Crossref]
- M Toporkiewicz, J Meissner, L Matusewicz, A Czogalla, AF Sikorski. Toward a Magic or Imaginary Bullet? Ligands for Drug Targeting to Cancer Cells: Principles, Hopes, and Challenges. Int Jf Nanomedicine 2015. [Google Scholar] [Crossref]
- MK Gurka, D Pender, P Chuong, BL Fouts, A Sobelov, MW Mcnally. Identification of Pancreatic Tumors in Vivo with Ligand-Targeted, PH Responsive Mesoporous Silica Nanoparticles by Multispectral Optoacoustic Tomography. J Controlled Release 2016. [Google Scholar] [Crossref]
- J Liu, J Liu, H Xu, Y Zhang, L Chu, Q Liu. Novel Tumor-Targeting, Self-Assembling Peptide Nanofiber as a Carrier for Effective Curcumin Delivery. Int J Nanomedicine 2013. [Google Scholar] [Crossref]
- DN Pandya, R Hantgan, MM Budzevich, ND Kock, DL Morse, I Batista. Preliminary Therapy Evaluation of 225Ac-DOTA-c (RGDyK) Demonstrates That Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for in Vivo Tumor Visualization.. Theranostics 2016. [Google Scholar] [Crossref]
- K Numata, J Hamasaki, B Subramanian, DL Kaplan. Gene Delivery Mediated by Recombinant Silk Proteins Containing Cationic and Cell Binding Motifs. J Controlled Release 2010. [Google Scholar]
- D Porciani, L Tedeschi, L Marchetti, L Citti, V Piazza, F Beltram. Aptamer-Mediated Codelivery of Doxorubicin and NF-ΚB Decoy Enhances Chemosensitivity of Pancreatic Tumor Cells. Mol Ther - Nucleic Acids 2015. [Google Scholar] [Crossref]
- J Despanie, J P Dhandhukia, S F Hamm-Alvarez, J A Mackay. Elastin-like Polypeptides: Therapeutic Applications for an Emerging Class of Nanomedicines. Journal of Controlled Release2016 . [Google Scholar]
- P S Thakuri, C Liu, G D Luker, H Tavana. Biomaterials-Based Approaches to Tumor Spheroid and Organoid Modeling. Adv Healthcare Mater 2018. [Google Scholar] [Crossref]
- J Lu, W Zhao, Y Huang, H Liu, R Marquez, R B Gibbs, J Li, R Venkataramanan, L Xu, S Li, S Li, S Li. Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier. Molecular Pharmaceutics2015 . [Google Scholar]
- J Adijanto, M I Naash. Nanoparticle-Based Technologies for Retinal Gene Therapy. Eur J Pharm Biopharmaceutics 2015. [Google Scholar] [Crossref]
- MO Abdalla, P Karna, H K Sajja, H Mao, C Yates, T Turner. Enhanced Noscapine Delivery Using UPAR-Targeted Optical-MR Imaging Trackable Nanoparticles for Prostate Cancer Therapy. J Controlled Release 2011. [Google Scholar]
- SH Tseng, MY Chou, IM Chu. Cetuximab-Conjugated Iron Oxide Nanoparticles for Cancer Imaging and Therapy. Int J Nanomedicine 2015. [Google Scholar] [Crossref]
- Y Zhang, JW Chan, A Moretti, KE Uhrich. Designing Polymers with Sugar-Based Advantages for Bioactive Delivery Applications. J Controlled Release 2015. [Google Scholar] [Crossref]
- P Ray, MA Cheek, ML Sharaf, N Li, AD Ellington, BA Sullenger. Aptamer-Mediated Delivery of Chemotherapy to Pancreatic Cancer Cells. Nucleic Acid Therapeutics 2012. [Google Scholar] [Crossref]
- P Yingchoncharoen, DS Kalinowski, DR Richardson. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is yet to Come. Pharmacol Rev 2016. [Google Scholar] [Crossref]
- T Stylianopoulos, R K Jain. Design considerations for nanotherapeutics in oncology. Nanomedicine 2015. [Google Scholar] [Crossref]
- A Shergalis, A Bankhead, U Luesakul, N Muangsin, N Neamati. Current Challenges and Opportunities in Treating Glioblastomas. Pharmacol Rev 2018. [Google Scholar] [Crossref]
- T Yang, B Li, S Qi, Y Liu, Y Gai, P Ye. Co-Delivery of Doxorubicin and Bmil SiRNA by Folate Receptor Targeted Liposomes Exhibits Enhanced Anti-Tumor Effects in Vitro and in Vivo. Theranostics 2014. [Google Scholar] [Crossref]
- CJ Gannon, CR Patra, R Bhattacharya, P Mukherjee, SA Curley. Intracellular Gold Nanoparticles Enhance Non-Invasive Radiofrequency Thermal Destruction of Human Gastrointestinal Cancer Cells. J Nanobiotechnol 2008. [Google Scholar] [Crossref]
- J Lee, DG Jo, D Park, HY Chung, MP Mattson. Adaptive Cellular Stress Pathways as Therapeutic Targets of Dietary Phytochemicals: Focus on the Nervous System. Pharmacol Rev 2014. [Google Scholar] [Crossref]